Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

DISEASE CHARACTERISTICS: * Undergoing cytologic chemotherapy for hematological/oncological disease * Must meet all of the following criteria: * Documented mannose-binding lectin (MBL) levels \< 300 ng/mm³ within the past week * Fever (oral temperature \> 100.4° F) * Neutropenia, defined as absolute neutrophil count ≤ 1,000/mm³ with the anticipation that the counts will fall below 500/mm\^3 * Receiving broad spectrum antibiotic therapy for fever and neutropenia PATIENT CHARACTERISTICS: * No serious illness, in the opinion of the principal investigator, that would preclude study compliance * No known allergic reactions to mannose-binding lectin or other human plasma products * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier method contraception during and for ≥ 30 days after completion of study treatment * AST and ALT ≤ 5 times upper limit of normal (ULN) * Bilirubin ≤ 2.5 times ULN * Creatinine clearance \> 60 mL/min OR creatinine based on age as follows: * No more than 0.8 mg/dL (for patients 5 years of age and under) * No more than 1.0 mg/dL (for patients 6-9 years of age) * No more than 1.2 mg/dL (for patients 10-12 years of age) * No more than 1.4 mg/dL (for patients over 13 years of age \[female\]) * No more than 1.5 mg/dL (for patients 13-15 years of age \[male\]) * No more than 1.7 mg/dL (for patients of 16 years of age \[male\]) * No poor venous access that would preclude IV drug delivery or multi…